Non-interventional Study of Ectoin Nasal Douche (END01) in Patients With Acute Viral Rhinosinusitis
NCT ID: NCT03480100
Last Updated: 2018-07-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
120 participants
OBSERVATIONAL
2017-11-27
2018-05-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
It will be investigated if the dosis of the used decongestant nasal spray might be reduced, the development of the disease might be positively influenced and/or the potentially occuring side effects (e.g. dryness of the nasal mucosa, sneezing) might be alleviated by using the Ectoin Nasal Douche as concomitant therapy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Non-interventional Study With Ectoin Containing and/or Decongesting Nasal Spray in Patients With Rhinosinusitis
NCT03693976
Application of Ectoin® Rhinitis Nasal Spray in Patients With Acute Rhinosinusitis
NCT01684540
Nasal Steroids, Irrigation, Oral Antibiotics, and Subgroup Targeting for Effective Management of Sinusitis
NCT06076304
The Effect of Facial Effleurage on Acute Rhinosinusitis
NCT04642989
A Study of an Experimental Nasal Spray in Subjects With Early Signs of the Common Cold
NCT01488604
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Efficacy will be studied by documentation of the following symptoms:
* oedema, redness (assessed by rhinoscopy)
* nasal obstruction, nasal secretion, headache/face pain, loss of sense of smell/taste
* sore throat, cough
In parallel, participating patients will document their symptoms and the their quality of life over the entire study duration in patient diaries.
Patients of both genders aged 6 years and above can take part in the study if diagnosed with acute viral rhinosinusitis. The assignment of a patient to a particular treatment is not decided in advance but falls within current practice, and is clearly separated from the decision to include the patient into the study.
Study therapy will be applied in accordance with the respective instructions for use.
Study duration is 7-14 days, depending on the improvement of symptoms. At the end of the study, both the investigators and the patients are asked to judge the efficacy and tolerability of the treatments.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Xylometazoline Nasal spray
1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day
Xylometazoline Nasal Spray
Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Xylometazoline + Ectoin Nasal Douche
Xylometazoline: 1 spray per nostril as often as required but not exceeding 3 sprays per nostril per day, Ectoin Nasal Douche (END01): 1 spray per nostril 2-6 times per day or as often as required
Xylometazoline Nasal Spray
Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Ectoin Nasal Douche
Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Xylometazoline Nasal Spray
Application of Xylometazoline Nasal Spray in accordance with the instructions for use
Ectoin Nasal Douche
Application of Ectoin Nasal Douche (END01) in accordance with the instructions for use
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* presence of common cold symptoms
Exclusion Criteria
* acute bacterial rhinosinusitis
* chronic rhinosinusitis
6 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bitop AG
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andreas Bilstein, Dr.
Role: STUDY_DIRECTOR
CSO
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
bitop AG
Witten, North Rhine-Westphalia, Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
PPL-106
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.